Aldevron News: Research Grade Manufacturing

In the News: Aldevron Expands Manufacturing Capabilities in Madison

On February 10, Aldevron hosted a virtual celebration of its lab facility expansion in Madison.
 
Aldevron produces the raw materials that allow clients to make groundbreaking therapies, and its protein business unit has operated within University Research Park since 2009. The facility’s growth from 8,000 to nearly 30,000 square feet includes a new 3,500-square-foot fermentation suite and will allow the company to expand its projects’ scope and scale.
 
Read the full article from University of Wisconsin-Madison   here.
 
Additionally, Tom Foti, President of Aldevron's Protein Business Unit provided a virtual tour, which you can view below!
Read More

In the News: Aldevron Now Offering AAV Rep/Cap Plasmids For Viral Vector Production

Aldevron announced today the immediate availability of rep/cap plasmids pALD-AAV2, AAV5 and AAV6 to support AAV viral vector manufacturing. All three rep/cap plasmids are immediately available at Research Grade. Additionally, pALD-AAV6 is immediately available at the GMP-Source® quality level, while pALD-AAV2 and pALD-AAV5 will be made available based on market demand. The plasmids are royalty free for all applications in support of pre-clinical activities through clinical development and commercial production.

Read More

In the News: Pharma's Almanac - The Pivotal Role of Plasmid DNA

Plasmid DNA was key to the development of biologic drug manufacturing. Today, it plays a critical role in the production of next-generation cell and gene therapies and vaccines. With its plasmid DNA manufacturing expertise, Aldevron has helped facilitate the advance of these important therapeutics. The company continues to invest in additional capacity and novel capabilities to support biopharma manufacturers into the future.

Read More

Aldevron's Plasmids Used In Cancer Prevention Vaccine Trial

Aldevron client and partner, Calviri, testing vaccine to prevent cancer in trial using 800 dogs

Aldevron has the privilege of working with thousands of clients trying to solve the world’s biggest health challenges and cancer is at the top of the list. Finding a preventative therapy has long been the goal. Our partner, Calviri, is testing a vaccine in a canine trial that could lead to a treatment for humans.

Read More

New Standardized Plasmids Available for Lentiviral Manufacturing

Novel Packaging and Expression Plasmids Promise to Reduce Gene Therapy Manufacturing Costs and Delivery Times

Miami, FL - Aldevron announced from Phacilitate Leaders World in Miami the immediate availability of standardized plasmids for lentiviral production through a license agreement with Oxford Genetics.

Read More